Targeted therapies: Selumetinib MEKing differences in NF1
- PMID: 28094260
- DOI: 10.1038/nrclinonc.2017.6
Targeted therapies: Selumetinib MEKing differences in NF1
Comment on
-
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. N Engl J Med. 2016. PMID: 28029918 Free PMC article. Clinical Trial.
References
-
- N Engl J Med. 2016 Dec 29;375(26):2550-2560 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
